What are tumour markers?

• Introduction
• Abortion
• Amenorrhoea
• Birth Control
• Bladder Symptoms
• Cancer in Women
• What is cancer?
• Cancer Staging
• Prevalence
• Familial Cancer
• Symptoms, Signs, Diagnosis
• Prevention
• Screening
• Emotional Effects
• Counselling
• Personality and Outcome
• Holistic Approach
• Breast Cancer
• Ovarian Cancer
• Cervical Cancer
• Endometrial Cancer
• Vulva, Vagina, Fall.Tubes
• Treatments
• Mortality
• Support Groups
• Childbirth
• Children and Teenagers
• Diet / Weight Loss
• Dysmenorrhoea
• Endometriosis
• Fibroids
• HRT
• Hirsutism
• Hysterectomy
• Infections
• Infertility
• Medication Drugs
• Menopause
• Menorrhagia
• Miscarriage
• Painful Sex
• Pap Smear Test
• PCOS
• Pelvic Pain
• PMS
• Postpartum
• Pregnancy
• Self Esteem
• Sexual Problems
• Vaginal Discharge
• Vaginal Prolapse
• Vulval Symptoms

Underperforming Family Website?

This website

2womenshealth.com

is the

most popular personal website

in its category

1.5 million visitors annually.

 

The author has applied

his clinical and

scientific research experience

to

Search Engine Optimization

the application of techniques to

promote your web pages.

 

 

Visit

KeywordSEOPro.com

Now

 

Promote Your

Family Website

 

Improve Your Business Income

 

Gynecol Oncol. 2006 Oct;103(1):195-8.

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.

Markman M,Federico M,Liu PY,Hannigan E,Alberts D.

University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. mmarkman@mdanderson.org

Objectives:

The relationship between survival and early changes in the serum level of the CA-125 antigen in patients with advanced ovarian cancer remains poorly defined.

Methods:

To explore this issue, the serum CA-125 values from 101 patients with advanced ovarian cancer who participated in a Southwest Oncology Group trial (SWOG 8412), which compared the systemic delivery of cisplatin/cyclophosphamide vs. carboplatin/cyclophosphamide (both delivered every 28 days for 6 cycles) in suboptimal residual stage III and IV ovarian cancer, were evaluated. All patients in this analysis had CA-125 values available for at least 8 weeks following initiation of chemotherapy. Cox proportional hazards regression was used in multivariate analysis to determine the prognostic significance of the CA-125 concentration.

Results:

While pretreatment CA-125 values did not correlate with survival, the concentration of this tumor marker 8 weeks after initiation of therapy was a powerful independent prognostic factor. The median survivals for patients (n = 51) with a CA-125< 35 U/ml, vs. patients (n = 50) with a CA-125 > 35 U/ml, at this time point, were 26 months and 15 months, respectively (P = 0.0001). Further, women with serum CA-125 values<50% of their pretreatment concentration at 8 weeks experienced a median survival of 21 months, compared to only 10 months for individuals with tumor marker levels >50% of their baseline value (P = 0.0003).

Conclusion:

Reduction in the serum CA-125 concentration over the initial two cycles of platinum-based chemotherapy is a powerful independent predictor of survival for patients with suboptimal stage III or IV ovarian cancer. Patients without significant declines in CA-125 after two cycles of platinum-based chemotherapy have a particularly poor prognosis.

Please click on the required question.

• 1 What is cancer (malignancy)
• 2 What is meant by cancer staging?
• 3 How prevalent is cancer?
• 4 How prevalent are womens' cancers?
• 5 What causes cancer?
• 6 Is cancer a hereditary condition?
• 7 How can gynaecological cancer present?
• 8 How can we reduce the risks of the womens' cancers?

   

  Reducing the Risks of Womens' Cancers.

• 9 What are screening tests?
• 10 What are the reactions to a diagnosis of cancer?
• 11 Is there a place for counselling when cancer is diagnosed?
• 12 Can personality alter the prognosis?
• 13 Is the incidence of deaths from the female cancers changing?
• 14 Is there a place for a holistic approach to cancer?

   

  Cancer of the Cervix.

• 15 How prevalent is cervical cancer?
• 16 What causes cervical cancer?
• 17 How long an interval should there be between cervical screening (smear) (PAP) tests?
• 18 Is there any evidence that cervical screening can reduce the incidence of cervical cancer?
• 19 Will pre-malignant changes of the cervix invariably lead to cancer?

   

  Endometrial Cancer (Uterus)

• 20 What causes endometrial cancer?
• 21 Are there screening tests for endometrial cancer?
• 22 How does endometrial cancer present?
• 22a How can endometrial cancer be prevented?
• 22b How can endometrial cancer be treated?

  Cancer of the Ovary.

• 23 How does ovarian cancer present?
• 24 How prevalent is ovarian cancer?
• 25 What are tumour markers?
• 26 Can we screen for ovarian cancer?
• 27 What is the relationship between infertility and ovarian cancer?
• 28 Can treatment of infertility increase the risk of ovarian cancer?
• 29 What is the relationship between oral contraception and cancer?
• 30 Can ovarian cancer be prevented?
• 31 I use talcum power. Could this increase my risk of developing ovarian cancer?

   

  The Treatment Of Womens' Cancers

• 32 Can we predict the course of a cancer?
• 33 What treatment options are available for gynaecological cancer?
• Q32.33c What treatment options are available for ovarian cancer?

  Cancer of the Vulva, Vagina and Fallopian Tube

• 34 How prevalent are malignant conditions of the vulva, vagina and Fallopian tubes?

  Breast Cancer

• 35 What is the incidence of breast cancer?
• 35 ?What is the cause of breast cancer?
• 35a What are the advantages of breast cancer screening - mammography - mammograms?
• 36 How often should breast screening be carried out?
• 37 Are there any problems having a mammogram?
• 38 Should I check myself for breast lumps?
• 39 One of my family developed cancer of the breast. Am I at increased risk?
• 40 We have a family tendency towards developing breast / ovarian cancer. Are there any genetic tests to find out if I am at increased risk?
• 41 What happens if a mammogram shows an abnormality?
• 42 What are the advantages and disadvantages of tamoxifen in the management of breast cancer?
• 42a Breast Cancer Treatment - What is available?
• 43 What is the relationship between breast cancer and the pill?

  Web sites and Support Groups

• 44 Are there any support groups?
• 44 Are there any support groups?
• 45 Support Groups.
• 46 Breast Cancer Support Groups
• 47 Ovarian Cancer Support Groups
• 48 Endometrial Cancer Support Groups
• 49 Cervical Cancer Support Groups
  
  
  

  
  
  

  Thank you for choosing to visit us.

  
  

  This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London - Specialist Interests - Reproductive Medicine including Infertility, PCOS, PMS, Menopause and HRT.

  I do hope that you find the answers to your women's health questions in the patient information and medical advice provided.